Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.39 |
| ▸ | TK2 | O00142 | 3/20 | 0.34 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PYGM | P11217 | 1/20 | 0.33 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.33 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.33 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.33 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27784868 | 0.91 | MAPT (0.42) | TYMPSLC5A2PYGM | |
| SCHEMBL9135382 | 0.85 | LGALS9 (0.38) | TK2SLC5A2LGALS9LGALS1LGALS3 | |
| SCHEMBL2922542 | 0.79 | TK1 (0.42) | TK2 | |
| SCHEMBL779334 | 0.79 | TK1 (0.42) | TK2 | |
| SCHEMBL6909059 | 0.77 | TMEM97 (0.47) | TYMPSLC5A2 | |
| SCHEMBL9092454 | 0.77 | TYMP (0.41) | TYMPPYGM | |
| SCHEMBL6908967 | 0.75 | TK2 (0.44) | TK2SLC5A2PYGM | |
| SCHEMBL16342011 | 0.74 | TYMP (0.40) | TYMPTK2PYGMLGALS9LGALS1 | |
| SCHEMBL9556857 | 0.74 | TYMP (0.39) | TYMPTK2SLC5A2PYGM | |
| SCHEMBL9711039 | 0.74 | SLC5A2 (0.44) | SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1204415-B1 | 5-(E)-BROMOVINYL URACIL ANALOGUES AND RELATED PYRIMIDINE NUCLEOSIDES AS ANTI-VIRAL AGENTS AND METHODS OF USE | UNIV YALE (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20040053891-A1 | 5-(E)-bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053891-A1 | 5-(E)-bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use | TYMP, DPYD, CXCL8 | TYMP 1/4885TK2 85/4885SLC5A2 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.